CNSP News and Press, CNS Pharmaceuticals Inc. From 05/15/24

Scientists from the University of Florida in America have designed a new vaccine for cancer that prompts the immune system to target glioblastoma. Glioblastoma is an aggressive type of cancer that forms in the spinal cord and/or brain. Roughly 19,000 people in the European Union are afflicted...

2024-05-09 17:38:38 ET More on CNS Pharmaceuticals Financial information for CNS Pharmaceuticals Read the full article on Seeking Alpha For further details see: CNS Pharmaceuticals files for $75M mixed shelf offering

Scientists at Purdue University are trying to develop a new treatment for glioblastoma tumors. Glioblastoma is a type of cancer that originates in the spinal cord and/or brain. This cancer is fatal, with a median time of survival of 14 months. Conventional treatments for other cancers, includ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced that its Chief Executive Officer John Climaco will present at the LSX World Congress 20...

Presentation on Monday, April 29 th at 4:15 PM (GMT+1) HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured on the Virtual Investor Lunch Break: The CNSP Opportunity event. During the l...

Live video webcast with Chief Executive Officer, John Climaco, on Tuesday, April 23 rd at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / April 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatm...

CNS Pharmaceuticals (NASDAQ: CNSP) , a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. “A biotech commercialization lead...

Scientists at the National Agency for Medicines and Health Products Safety in France recently linked the use of hormone treatments by women to a heightened risk of women developing benign brain tumors. During their research, they determined that prolonged use of some progestogen drugs was ass...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released financial results for the full year ending Dec. 31, 2023; the company also reported on corp...